Clinical application of iodine-131 radiotherapy combined with leucoge in post-operated patient with differentiated thyroid cancer

Objective: To investigate the feasibility of combined ¹³¹I and Leucoge curing the differentiated thyroid carcinoma after operation and in order to enhance the therapeutic compliance and efficacy in the thyroid cancer patients during therapy period. Methods: The information was collected and then had a retrospective analysis in 167 differentiated thyroid cancer patients with postoperative residual thyroid tissue, local recurrence or lymph node and systemic metastases. Total 167 patients were divided into 3 groups that was based on giving Leucogen tablets 20 mg tid (Group A, n = 47), 40 mg tid (Group B, n = 54) and 80 mg tid (Group C, n = 66) following post-treatment with ¹³¹I. The therapeutic effectiveness of ¹³¹I combined with Leucoge was evaluated during therapy period. Results: There were no change between three groups in sample size, age, WBC and PLT before curing of ¹³¹I (P > 0.05). The level of WBC and PLT in three groups had selective change after ¹³¹I treatment. The WBC and PLT levels in Group A and Group B had significantly decreased (P < 0.05) and no effect in Group C (P > 0.05). The efficacy of ¹³¹I on differentiated thyroid carcinoma with postoperative residual thyroid tissue, local and distant metastases was confirmed in this study. Conclusion: The combination of ¹³¹I and Leucoge is an effective cure on postoperative differentiated thyroid carcinoma to prevent the decrease of WBC and PLT as well as bone marrow suppression. (authors)